Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Parkinsonism & Related Disorders

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1353-8020(08)70017-8PMID 18267251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Memantine

  2012cited by this paper
• Neuroprotective Strategies in Parkinson’s Disease

  2009influential reference
• Drug discovery targeted to the Alzheimer’s APP mRNA 5′-untranslated region

  2007cited by this paper
• The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases

  2007cited by this paper
• Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro

  2007cited by this paper
• Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.

  2007cited by this paper
• Therapeutic targets and potential of the novel brain‐ permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease 1

  2007cited by this paper
• Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.

  2007cited by this paper
• Multi-target therapeutics: when the whole is greater than the sum of the parts.

  2007cited by this paper
• The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.

  2006cited by this paper
• New targets for pharmacological intervention in the glutamatergic synapse.

  2006cited by this paper
• Multifunctional neuroprotective drugs for the treatment of cognitive and movement impairment disorders, including Alzheimer's and Parkinson's diseases

  2006cited by this paper
• Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases

  2006cited by this paper
• NGP1-01 is a Brain-permeable Dual Blocker of Neuronal Voltage- and Ligand-operated Calcium Channels

  2006cited by this paper
• Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders.

  2006cited by this paper
• The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.

  2006cited by this paper
• Reduction of iron‐regulated amyloid precursor protein and β‐amyloid peptide by (–)‐epigallocatechin‐3‐gallate in cell cultures: implications for iron chelation in Alzheimer's disease

  2006cited by this paper
• Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness

  2006cited by this paper
• Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

  2006cited by this paper
• Rasagiline

  2005cited by this paper
• Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds.

  2005cited by this paper
• Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B.

  2005cited by this paper
• Regulation of Bcl‐2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine

  2005cited by this paper
• Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice

  2005cited by this paper
• N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2

  2005cited by this paper
• Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition

  2005influential reference
• NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia.

  2005cited by this paper
• Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease

  2005cited by this paper
• Green tea polyphenol (–)‐epigallocatechin‐3‐gallate induces neurorescue of long‐term serum‐deprived PC12 cells and promotes neurite outgrowth

  2005cited by this paper
• Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess®/Comtan® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment

  2005cited by this paper
• Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.

  2005influential reference
• Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion

  2005influential reference
• CNS Targets for multi-functional drugs in the treatment of Alzheimer’s and Parkinson’s diseases

  2005cited by this paper
• Designed multiple ligands. An emerging drug discovery paradigm.

  2005cited by this paper
• Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.

  2005influential reference
• Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

  2005cited by this paper
• Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

  2005cited by this paper
• Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors.

  2005cited by this paper
• Novel Neuroprotective Mechanism of Action of Rasagiline Is Associated with Its Propargyl Moiety: Interaction of Bcl‐2 Family Members with PKC Pathway

  2005cited by this paper
• Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.

  2005cited by this paper
• TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition.

  2005cited by this paper
• TNFα potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NFκB inhibition

  2005cited by this paper
• Multifunctional Activities of Green Tea Catechins in Neuroprotection

  2005cited by this paper
• Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats.

  2004influential reference
• Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

  2004cited by this paper
• Metal and inflammatory targets for Alzheimer's disease.

  2004cited by this paper
• Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

  2004cited by this paper
• A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

  2004cited by this paper
• From magic bullets to designed multiple ligands.

  2004cited by this paper
• Parkinson's disease, pesticides and individual vulnerability.

  2004cited by this paper
• Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases.

  2004cited by this paper
• Pharmacological aspects of (-)-deprenyl.

  2004cited by this paper
• Monoamine oxidase-B inhibition in Alzheimer's disease.

  2004cited by this paper
• Iron, brain ageing and neurodegenerative disorders

  2004influential reference
• Synthesis and biological evaluation of pentacyclo[5.4.0.02,6.03,10.05,9]undecane derivatives as potential therapeutic agents in Parkinson's disease

  2004cited by this paper
• Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members

  2004cited by this paper
• Synthesis and biological evaluation of pentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecane derivatives as potential therapeutic agents in Parkinson's disease.

  2004cited by this paper
• Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.

  2004cited by this paper
• (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.

  2004cited by this paper
• Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor

  2004cited by this paper
• Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke

  2003cited by this paper
• Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B

  2003cited by this paper
• Neuroprotection by caffeine and adenosine A2A receptor blockade of β‐amyloid neurotoxicity

  2003cited by this paper
• Neuroprotective Strategies in Parkinson’s Disease

  2003cited by this paper
• Neuroprotection and neurorescue against Aβ toxicity and PKC‐dependent release of non‐amyloidogenic soluble precursor protein by green tea polyphenol (‐)‐epigallocatechin‐3‐gallate

  2003cited by this paper
• Animal models of stroke: do they have value for discovering neuroprotective agents?

  2003cited by this paper
• Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.

  2003cited by this paper
• Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion: adverse effects of hypothalamic damage and strategies for its avoidance.

  2003cited by this paper
• Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke

  2003cited by this paper
• Neuroprotection in Parkinson's disease: Clinical trials

  2003cited by this paper
• Screening of novel pentacyclo-undecylamines for neuroprotective activity.

  2003influential reference
• Neuroprotection by caffeine and adenosine A2A receptor blockade of β‐amyloid neurotoxicity

  2003cited by this paper
• Attenuation of MPTP‐induced dopaminergic neurotoxicity by TV3326, a cholinesterase‐monoamine oxidase inhibitor

  2003cited by this paper
• Monoamine oxidase B inhibition and neuroprotection

  2003cited by this paper
• Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.

  2002cited by this paper
• Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

  2002cited by this paper
• 8-(3-Chlorostyryl)caffeine May Attenuate MPTP Neurotoxicity through Dual Actions of Monoamine Oxidase Inhibition and A2A Receptor Antagonism*

  2002cited by this paper
• Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression

  2002cited by this paper
• NMDA receptor pathways as drug targets

  2002cited by this paper
• Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates.

  2002cited by this paper
• Selective effects of cyclodiene insecticides on dopamine release in mammalian synaptosomes.

  2002cited by this paper
• Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.

  2002cited by this paper
• Does caffeine intake protect from Alzheimer's disease?

  2002cited by this paper
• Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

  2001cited by this paper
• Metal chelation of polyphenols.

  2001cited by this paper
• Effects of pH and Metal Ions on Antioxidative Activities of Catechins

  2001cited by this paper
• Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa

  2000cited by this paper
• Age-related changes of MAO-A and -B distribution in human and mouse brain.

  2000cited by this paper
• Reduction of Edema and Infarction by Memantine and MK-801 After Focal Cerebral Ischaemia and Reperfusion in Rat

  2000cited by this paper
• MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?

  2000cited by this paper
• Calcium antagonists for acute ischemic stroke.

  2000cited by this paper
• Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells.

  2000cited by this paper
• Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.

  1999influential reference
• Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.

  1999cited by this paper
• Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.

  1999cited by this paper
• Ischemic cell death in brain neurons.

  1999cited by this paper
• Recent Developments in the Drug Treatment of Alzheimer’s Disease

  1999cited by this paper
• Pharmacology of Pramipexole, a Dopamine D3-Preferring Agonist Useful in Treating Parkinson's Disease

  1998cited by this paper
• Parkinson's disease. First of two parts.

  1998cited by this paper

• Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin

  2023cites this paper
• Fungal endophytes as a potential source of therapeutically important metabolites

  2021cites this paper
• Potentiating the Benefits of Melatonin through Chemical Functionalization: Possible Impact on Multifactorial Neurodegenerative Disorders

  2021cites this paper
• Open and rearranged norbornane derived polycyclic cage molecules as potential neuroprotective agents through attenuation of MPP+- and calcium overload-induced excitotoxicity in neuroblastoma SH-SY5Y cells.

  2020cites this paper
• 4-Oxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione Derivatives as NMDA Receptor- and VGCC Blockers with Neuroprotective Potential

  2020cites this paper
• Fraternine, a Novel Wasp Peptide, Protects against Motor Impairments in 6-OHDA Model of Parkinsonism

  2020influential citation
• Therapeutic Potentials of Curcumin in Parkinson’s Disease

  2019cites this paper
• Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein

  2019cites this paper
• Non-human primate models of PD to test novel therapies

  2018cites this paper
• Polycyclic compounds as carriers for neuroactive non- steroidal anti-inflammatory drugs

  2017cites this paper
• Natural Neuroprotectives for the Management of Parkinson's Disease

  2017cites this paper
• Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson’s Disease Dual Target Ligands

  2017cites this paper
• Synthesis, characterization and biological activity of 2-(5-arylidene-2,4-dioxotetrahydrothiazole-3-yl)propanoic acid derivatives

  2017cites this paper
• Competitive Intelligence–based Lead Generation and Fast Follower Approaches

  2016cites this paper
• Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders.

  2016cites this paper
• Rational drug discovery design approaches for treating Parkinson’s disease

  2015cites this paper
• Improved virtual screening performance through docking scoring fusion in the discovery of dual target ligands for Parkinson’s disease

  2015cites this paper
• Virtual screening tailored ensembles of QSAR models for the discovery of dual A2A Adenosine Receptor Antagonists / Monoamine Oxidase B Inhibitors

  2015cites this paper
• Identification of novel scaffolds for Monoamine oxidase B inhibitors

  2014cites this paper
• Flavonoids with Novel Nicotinic Activity as Potential Pharmacotherapies to Treat Ethanol- Induced Neurotoxicity

  2014cites this paper
• Multifunctional compounds: smart molecules for multifactorial diseases.

  2014cites this paper
• A novel tetramethylpyrazine bis-nitrone (TN-2) protects against 6-hydroxyldopamine-induced neurotoxicity via modulation of the NF-κB and the PKCα/PI3-K/Akt pathways.

  2014cites this paper
• Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.

  2014cites this paper
• The Novel Tetramethylpyrazine Bis-nitrone (TN-2) Protects Against MPTP/MPP+-Induced Neurotoxicity via Inhibition of Mitochondrial-Dependent Apoptosis

  2014cites this paper
• Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders

  2013cites this paper
• Involvement of CRH Receptors in the Neuroprotective Action of R-Apomorphine in the Striatal 6-OHDA Rat Model

  2013cites this paper
• Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

  2013cites this paper
• Ampelopsis Radix Protects Dopaminergic Neurons against 1-Methyl-4-phenylpyridinium/1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Toxicity in Parkinson's Disease Models In Vitro and In Vivo

  2013cites this paper
• Rationally designed multi-targeted agents against neurodegenerative diseases.

  2013cites this paper
• Why is homocysteine toxic for the nervous and immune systems?

  2013cites this paper
• Novel adamantane derivatives as multifunctional neuroprotective agents

  2013cites this paper
• The role of fragment-based and computational methods in polypharmacology.

  2012cites this paper
• Structure-based design, synthesis, molecular docking, and biological activities of 2-(3-benzoylphenyl) propanoic acid derivatives as dual mechanism drugs

  2012cites this paper
• Polycyclic Cage Structures as Lipophilic Scaffolds for Neuroactive Drugs

  2012cites this paper
• Discovery of MAO-B inhibitors - present status and future directions part I: oxygen heterocycles and analogs.

  2012cites this paper
• 3.231 CHEMICALS POSSESSING A NEUROTROPHIN-LIKE ACTIVITY ON DOPAMINERGIC NEURONS IN PRIMARY CULTURE

  2012cites this paper
• Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B.

  2011cites this paper
• Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

  2011cites this paper
• Oxidative Stress in Neurodegenerative Diseases: Mechanisms and Therapeutic Perspectives

  2011cites this paper
• Effect of the Mk801 and (-) Nicotine Intracerebral Administration on Glu and Gaba Extracellular Concentration in the Pedunculopontine Nucleus from Rats

  2011cites this paper
• Thermodynamic analysis of the molecular interactions between amyloid beta-peptide 42 and (-)-epigallocatechin-3-gallate.

  2010cites this paper
• Oxidative stress and Alzheimer’s disease: dietary polyphenols as potential therapeutic agents

  2010cites this paper
• Efecto neuroprotector de la administración sistémica de MK-801 en el núcleo pedunculopontino de ratas hemiparkinsonizadas

  2009cites this paper
• Chemicals Possessing a Neurotrophin-Like Activity on Dopaminergic Neurons in Primary Culture

  2009cites this paper
• Effects of a novel dopamine uptake inhibitor upon extracellular dopamine from superfused murine striatal tissue.

  2009cites this paper
• Neuroprotective effect of the systemic administration of MK-801 on the pedunculopontine nucleus of hemiparkinsonian rats

  2009cites this paper
• Carnisone Increases Efficiency of DOPA Therapy of Parkinson's Disease: A Pilot Study

  2008cites this paper
• Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?

  2008cites this paper